Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching entecavir or tenofovir disoproxil to tenofovir alafenamide in chronic hepatitis B
ChiCTR2300067323Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (4 cohorts), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: urine protein. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2300067323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067323.